Latest

Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆

Sreepriya Prasannan

Sreepriya Prasannan

Life Science Journalist & Editor

Sreepriya Prasannan is the Founder and Lead Editor of Priya Life Science. With a deep passion for the Irish pharmaceutical and MedTech sectors, she specializes in sharing actionable career insights, digital regulatory trends, and GMP compliance strategies.

5

Articles

7

Topics

1219

Min Published

Filter: All 5 Industry 75 Regulatory Affairs 42 Pharmaceutical 25 Biotechnology 16 MedTech 16 LinkedIn 12 Clinical Trials 5

Articles in Clinical Trials

5 articles

ASCO 2026 Highlights: Landmark Clinical Data Points to Survival Extensions in Pancreatic and Lung Cancers

Clinical Trials

ASCO 2026 Highlights: Landmark Clinical Data Points to Survival Extensions in Pancreatic and Lung Cancers

The annual ASCO conference has delivered landmark clinical trial results, bringing promising survival extensions for pancreatic cancer and targeted lung cancer therapies.

29 Jun 2026 5 min

The 2026 Obesity Power Rankings: Which Pharma Giants Can Break the Lilly-Novo Duopoly?

Clinical Trials

The 2026 Obesity Power Rankings: Which Pharma Giants Can Break the Lilly-Novo Duopoly?

With the obesity market projected to exceed $130 billion by 2034, we analyze the top 10 pharmaceutical companies vying for dominance. Explore our comprehensive Power Rankings assessing pipeline depth, clinical differentiation, and commercial infrastructure.

25 Jun 2026 5 min

Helus Pharma Secures US$50M Offering as MDD Trial Surpasses 86% Enrollment

Clinical Trials

Helus Pharma Secures US$50M Offering as MDD Trial Surpasses 86% Enrollment

Helus Pharma announces a $50 million offering to progress Phase 3 trials for their novel serotonergic agonists, alongside major clinical milestones and leadership updates.

25 Jun 2026 5 min

J-Pharma and Uniphar Advance Nanvuranlat into Global Phase III Trial for Biliary Tract Cancer

Clinical Trials

J-Pharma and Uniphar Advance Nanvuranlat into Global Phase III Trial for Biliary Tract Cancer

Japanese biotech J-Pharma and Ireland-based Uniphar have received FDA alignment to bypass Phase II and advance nanvuranlat (JPH203) directly into a pivotal global Phase III study for second-line biliary tract cancer.

18 Jun 2026 4 min

Navigating Challenges in Oncology: Jazz Pharmaceuticals and PharmaMar Stay Committed Despite Phase 3 Setback

Clinical Trials

Navigating Challenges in Oncology: Jazz Pharmaceuticals and PharmaMar Stay Committed Despite Phase 3 Setback

In the rigorous and highly demanding landscape of oncology research, scientific progress is often non-linear. Recently, Jazz Pharmaceuticals and its partner PharmaMar announced that their Phase 3 trial evaluating Zepzelca did not meet its primary endpoint.

16 Jun 2026 5 min